Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016025581 - METHOD FOR THE TREATMENT OF DEPRESSION

Publication Number WO/2016/025581
Publication Date 18.02.2016
International Application No. PCT/US2015/044830
International Filing Date 12.08.2015
IPC
A61K 31/135 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
A61K 31/137 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61M 11/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
11Sprayers or atomisers specially adapted for therapeutic purposes
A61K 31/35 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
CPC
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
Applicants
  • JANSSEN PHARMACEUTICA NV [BE]/[BE]
Inventors
  • LI, Qingqin, S.
  • DREVETS, Wayne, C.
Agents
  • PLANTZ, Bernard, F.
Priority Data
62/036,89613.08.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR THE TREATMENT OF DEPRESSION
(FR) MÉTHODE DE TRAITEMENT DE LA DÉPRESSION
Abstract
(EN)
The present invention is directed to a method for the treatment of depression, for example, treatment of resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at single nucleotide polymorphism (SNP) rs4306882. Specifically, the method comprising determining the presence of a G or T allele at rs4306882, and administering a dosing regimen of ketamine or esketamine, wherein the dosing regimen is adjusted to provide a higher dose and/or greater frequency of the ketamine or esketamine to those patients with the G allele (rather than T allele) at the polymorphic site of rs4306882. Further disclosed is a method for predicting whether a patient suffering from depression is genetically predisposed to poorly respond to antidepressants which block the reuptake of monoamine neurotransmitters, comprising genotyping said patient to determine the patient's genotype at SNP rs4306882.
(FR)
La présente invention concerne une méthode de traitement de la dépression, par exemple, de la dépression résistante au traitement dans le cadre de laquelle le schéma de traitement est ajusté en fonction du génotype du patient au niveau du polymorphisme mononucléotidique (SNP) rs4306882. Cette méthode comprend, plus précisément, les étapes consistant à déterminer la présence d'un allèle G ou T au niveau du SNP rs4306882 et à administrer un schéma posologique à base de kétamine ou d'eskétamine, ledit schéma posologique étant ajusté pour permettre l'administration d'une dose supérieure de kétamine ou d'eskétamine et/ou pour assurer une plus grande fréquence d'administration de ces substances aux patients porteurs de l'allèle G (plutôt que de l'allèle T) au niveau du site du SNP rs4306882. L'invention concerne également un procédé permettant de prédire si un patient souffrant de dépression est génétiquement prédisposé à ne répondre que médiocrement à des antidépresseurs qui inhibent la recapture des neurotransmetteurs monoaminergiques, ledit procédé consistant à génotyper ledit patient pour déterminer son génotype au niveau du SNP rs4306882.
Latest bibliographic data on file with the International Bureau